archer reveal ctDNA 28

Detecting meaningful mutations
from liquid biopsies by Anchored
Multiplex PCR (AMP®)

archer reveal ctdna logo

Detecting meaningful mutations from liquid biopsies by Anchored Multiplex PCR

Watch the webinar below


Liquid biopsies have the potential to be a less invasive method than traditional biopsies to detect advanced solid tumor mutational status.

Cell free DNA (cfDNA) can be profiled from liquid biopsy samples, although the abundance is generally low, ranging from less than 1ng to 30ng cfDNA per mL blood in healthy individuals. Furthermore, only a small fraction of cfDNA originates from tumor cells as circulating tumor DNA (ctDNA), except in more advanced disease states.

This ctDNA is typically highly fragmented (100-300bp), and thus NGS-based methods to detect oncogenic mutations from liquid biopsies must be sensitive enough to detect low-frequency mutations (allele fractions less than 2%) from low inputs (10-100ng) of highly fragmented material.

In this webinar, Josh Stahl and Jonathan Doose from ArcherDX describe AMP-based ctDNA library preparation, highlighting the use and advantages of molecular barcoded adapters to unambiguously remove PCR duplicates, correct for PCR or sequencer-derived sequence errors, and flag run-to-run contamination. They talk about how the AMP-powered Archer® Reveal ctDNA™ 28 kit combines robust variant detection and quantitative analysis with single-day library prep for powerful, accurate and fast mutation analysis from liquid biopsies.

Learning objective 1: Understand both the value of mutation analysis from ctDNA in liquid biopsies and the challenges of analyzing ctDNA by next-generation sequencing.

Learning objective 2: Learn how the Archer Reveal ctDNA 28 kit uses Anchored Multiplex PCR target enrichment chemistry to detect and characterize ctDNA.

This webinar is hosted by labroots


Jonathan Doose

About Jonathon Doose

Jonathan Doose completed his post-graduate studies at the University of California, Riverside where he investigated the molecular mechanism of CNS immune privilege in microglia and potential new therapeutic targets in neurodegenerative autoimmune diseases.

He joined ArcherDX in early 2016 and manages FusionPlex and VariantPlex assay development. Jonathan was essential in bringing the Archer Reveal ctDNA assay to market and continues to harness his scientific expertise to develop new applications for Archer technology.

Josh Stahl

About Josh Stahl

Originally from Baltimore, MD, Josh Stahl studied biochemistry and molecular biology at West Virginia University. He went to graduate school at the University of Colorado, Boulder, working on protein-protein interactions in morphine analgesia.

Josh joined ArcherDX in 2013, and has overseen biochemistry, molecular biology, and software development since that time. Now general manager and chief scientific officer, Josh continues to lead Archer R&D, product development and operations teams in developing new applications and Archer technology.

Subscribe to stay in the loop

How to contact us


2477 55th Street, Suite 202

Boulder, CO 80301


Phone: (877) 771 1093

Phone: (303) 357 9001

All content © 2018 ArcherDX, Inc.

For Research Use Only. Not for use in diagnostic procedures. For Research Use Only. Not for use in diagnostic procedures.